Despite the tremendous increase in understanding of basic cancer mechanisms and potential targets there has only been a moderate increase in effective new therapies to treat cancer.  With the ever growing costs of bringing new drugs to market, there is increasing conservatism in what is considered a promising new target to develop drugs against. The primary focus of the Gray lab is to develop inhibitors for wild-type and mutant forms of protein kinases that can be used for pharmacological validation experiments.

Most Notable Contributions Since 2000

Collaborative Labs